ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer

Shen, Xiangfeng; Zhao, Yuan; Liu, Guolong; Zhou, Hong-Lan; Fan, Jingjing; Zhang, Lihong; Li, Yu-Lin; Wang, Yishu*; Liang, Jiyong*; Xu, Zhi-Xiang*吉林大学; 1
Life Sciences2020-9-1DOI: 10.1016/j.lfs.2020.117923
22被引8阅读
引用收藏
分享

摘要

Aims: Liver kinase B1 (LKB1) deficiency is associated with reduced expression of programmed death ligand 1 (PD-L1) and inferior clinical outcomes of PD-1/PD-L1 blockade in non-small cell lung cancer (NSCLC). This study aimed to investigate the mechanism by which LKB1 regulates PD-L1 expression and its role in programmed death 1 (PD-1) blockade therapy in NSCLC. @@@ Main methods: The impact of LKB1 on PD-L1 was assessed by western blot, qRT-PCR and immunohistochemistry in NSCLC. Activators/inhibitors of AMPK and NRF2 were applied to explore the mechanisms underlying the regulation of PD-L1 by LKB1. Efficiency of combined application of metformin and PD-1 blockade was evaluated in immunocompetent C57BL/6 mice. @@@ Key findings: A remarkable positive correlation between LKB1 and PD-L1 expression was demonstrated in NSCLC tissues. Knockdown of LKB1 decreased PD-L1 in TC-1 cells, whereas overexpression of LKB1 increased PD-L1 in A549 cells. We further characterized that AMPK mediated the upregulation of PD-L1 by LKB1. Inhibition of AMPK or NRF2 markedly reduced PD-L1 in LKB1-intact NSCLC cells. In contrast, activation of AMPK or NRF2 reversed PD-L1 expression in LKB1-deficient NSCLC cells. Combined administration of metformin and anti-PD-1 antibody efficiently inhibited the growth of LKB1-intact tumors, whereas no obvious suppression was observed in LKB1-deficient tumors. @@@ Significance: These findings demonstrated that LKB1 upregulates PD-L1 expression in NSCLC by activating the AMPK and KEAP1/NRF2 signaling. Activation of LKB1-AMPK with metformin improves the therapeutic effect of PD-1 blockade in NSCLC with wild-type LKB1.

学科与关键词

关键词
NSCLCLKB1AMPKMetforminPD-1PD-L1Immunotherapy
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Life Sciences
发表日期
2020-09-01
卷期
第 256 卷
页码
117923
DOI
10.1016/j.lfs.2020.117923
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81573087, 81772924]; International Cooperation Foundation of Jilin Province [20190701006GH]

作者

  • S

    Shen, Xiangfeng (第一作者)

    jilin univ

  • Z

    Zhao, Yuan

    henan univ

查看全部 10 位作者收起作者
  • L

    Liu, Guolong

    1

  • Z

    Zhou, Hong-Lan

    1 · jilin univ

  • F

    Fan, Jingjing

    jilin univ

  • Z

    Zhang, Lihong

    jilin univ

  • L

    Li, Yu-Lin

    jilin univ

  • W

    Wang, Yishu (通讯)

    jilin univ

  • L

    Liang, Jiyong (通讯)

  • X

    Xu, Zhi-Xiang (通讯)

    jilin univ · henan univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417